Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

American Journal of Clinical Pathology

Volumn 119, Issue 6, 2003, Pages 824-832

  Kampalath, Bal ^a   Barcos, Maurice P ^b   Stewart, Carleton ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Aberrant marker; CD10; CD13; CD2; CD33; CD34; CD7; Chronic lymphocytic leukemia; Small lymphocytic lymphoma

Indexed keywords

CD19 ANTIGEN; CD2 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; MICROSOMAL AMINOPEPTIDASE; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MEMBRANE METALLOENDOPEPTIDASE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FLOW CYTOMETRY; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; THREE DIMENSIONAL IMAGING; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD13; ANTIGENS, CD19; ANTIGENS, CD2; ANTIGENS, CD34; ANTIGENS, CD7; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; B-LYMPHOCYTES; BONE MARROW; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPH NODES; LYMPHOMA, SMALL LYMPHOCYTIC; MALE; MIDDLE AGED; NEPRILYSIN; SURVIVAL RATE;

EID: 85047687769     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/4AGUT3LKEURD7T7K     Document Type: Article

References (49)

1. Sobol RE, Mick R, Royston I, et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med. 1987;316:1111-1117.
2. Matutes E, Catovsky D. The value of scoring systems for the diagnosis of biphenotypic leukemia and mature B-cell diseases. Leuk Lymphoma. 1994;13:11-14.
3. Buccheri V, Matutes E, Dyer MJS, et al. Lineage commitment in biphenotypic acute leukemia. Leukemia. 1993;7:919-927.
4. Bradstock KF, Kirk J, Grimsley PG, et al. Unusual immunophenotypes in acute leukemias: incidence and clinical correlations. Br J Haematol. 1989;72:512-518.
5. Urbano-Ispizua A, Matutes E, Villamor N, et al. Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukemia. Br J Haematol. 1990;75:202-207.
6. Kita K, Miwa H, Nakase K, et al. Clinical importance of CD7 expression in acute myelocytic leukemia: the Japan Cooperative Group of Leukemia/Lymphoma. Blood. 1993;81:2399-2405.
7. Slymen DJ, Miller TP, Lippman SM, et al. Immunobiologic factors predictive of clinical outcome in diffuse large cell lymphoma. J Clin Oncol. 1990;8:986-993.
8. Armitage JO, Vose JM, Linder J, et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1989;7:1783-1790.
9. Schmidt CJ, Dominico L, Ward P, et al. Aberrant antigen expression detected by three color flow cytometry in intermediate and high grade B-cell lymphomas. Leuk Lymphoma. 1999;34:539-544.
10. Grogan TM, Durie BG, Spier CM, et al. Myelomonocytic antigen positive multiple myeloma. Blood. 1989;73:763-769.
11. Durie BG, Grogan TM. CALLA-positive myeloma: an aggressive subtype with poor survival. Blood. 1985;66:229-232.
12. Spier CM, Grogan TM, Durie BG, et al. T-cell antigen-positive multiple myeloma. Mod Pathol. 1990;3:302-307.
13. Pinto A, Del Vecchio L, Carbone A, et al. Expression of myelomonocytic antigens is associated with unfavourable clinicoprognostic factors in B-cell chronic lymphocytic leukaemia. Ann Oncol. 1991;2(suppl 2):107-113.
14. Viciana AL, Lancet FC, Chamizo W, et al. Simultaneous expression of CD2 on a B-cell, small lymphocytic neoplasm. Cytometry. 1994;18:42-48.
15. Matures E, Wechsler R, Gomez WR, et al. Unusual T-cell phenotype in advanced B-chronic lymphocytic leukemia. Br J Haematol. 1981;49:635-642.
16. Kaleem Z, White G, Zutter M. Aberrant expression of T-cell-associated antigens on B-cell non-Hodgkin lymphoma. Am J Clin Pathol. 2001;115:396-403.
17. Molica S, Dattilo A. CD10 expression in B-chronic lymphocytic leukemia [letter]. Eur J Cancer. 1992;28A:1771.
18. Cacciola E, Giustolisi R, Guglielmo P. CALLA (CD10) positive lymphocytes in chronic lymphocytic leukemia [abstract]. Blood. 1989;743(suppl 1):40a.
19. Polliack A, Rabinowitz R, Luzorowitz R, et al. Myelomonocytic antigens are rarely expressed on Blymphocytic leukemia cells. Leuk Lymphoma. 1993;9:125-131.
20. Pinto A, Zagonel V, Carbone A, et al. Expression of myeloid associated antigens in chronic lymphocytic leukaemia [letter]. Br J Haematol. 1992;82:173-175.
21. Pinto A, Colletta G, Del Vecchio L, et al. c-fos oncogene expression in human hematopoietic malignancies is restricted to acute leukemias with monocytic phenotype and to subsets of B cell leukemias. Blood. 1987;70:1450-1457.
22. Nakase K, Kita K, Shiku H, et al. Myeloid antigen, CD13, CD14 and/or CD33 expression is restricted to certain lymphoid neoplasms. Am J Clin Pathol. 1996;105:761-768.
23. Kurec AS, Threatte GA, Gottlieb AJ, et al. Immunophenotypic subclassification of chronic lymphocytic leukemia. Br J Haematol. 1992;81:45-51.
24. Newman RA, Peterson B, Davey FR, et al. Phenotypic markers and bcl-1 gene rearrangement in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study. Blood. 1993;82:1239-1246.
25. Gahn B, Shafer C, Neef J, et al. Detection of trisomy 12 and Rb-deletion in CD34+ cells of patients with B-cell chronic lymphocytic leukemia. Blood. 1997;89:4275-4281.
26. Hanson CA, Gribbin TE, Schnitzer B, et al. CD11C (Leu-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. Blood. 1990;76:2360-2367.
27. Morabito F, Prasthofer EF, Dunlap NE, et al. Expression of myelomonocytic antigens on chronic lymphocytic leukemia B cells correlates with their ability to produce interleukin 1. Blood. 1987;70:1750-1757.
28. Tefferi A, Bartholmai BJ, Witzig TE, et al. Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 1996;106:457-461.
29. Tassies D, Montserrat E, Reverter JC, et al. Myelomonocytic antigens in B-cell chronic lymphocytic leukemia. Leuk Res. 1995;19:841-848.
30. Khalidi H, Medeiros LJ, Chang KL, et al. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol. 1998;109:211-220.
31. Rai KR, Patel DV. Chronic lymphocytic leukemia. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. Philadelphia, PA: Churchill Livingstone; 2000:1350-1363.
32. Stewart CC, Stewart SJ. Titering antibodies. In: Robinson JP, Darzynkiewicz Z, Dean P, et al, eds. Current Protocols in Cytometry. New York, NY: Wiley & Sons; 1997:4.1.1-4.1.13.
33. Stewart CC, Stewart SJ. Immunophenotyping. In: Robinson JP, Darzynkiewicz Z, Dean P, et al, eds. Current Protocols in Cytometry. New York, NY: Wiley & Sons; 1997:6.2.1-6.2.15.
34. Stewart CC, Stewart SJ. Cell preparation for the identification of leukocytes. In: Darzynkiewicz Z, Crissman H, Robinson JP, eds. Methods in Cell Biology. Vol 64. New York, NY: Academic Press; 2001:218-270.
35. Riedy MC, Muirhead KA, Jensen CP, et al. Use of photolabeling technique to identify nonviable cells in fixed homologous or heterologous cell populations. Cytometry. 199;112:133-139.
36. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
37. Estrov Z, Zipf TF, O'Brien S, et al. Identification of chronic lymphocytic leukemia (CLL) progenitor cells [abstract]. Blood. 1994:84(suppl 1):458a.
38. Pui CH, Dahl GV, Melvin S, et al. Acute leukemia with lymphoid and myeloid phenotype. Br J Haematol. 1984;56:121-130.
39. Schmitt-Graff A, Jurgens H, Reifenhausen A, et al. Childhood biphenotypic leukemia: detection of mixed lymphoid and myeloid populations in bone marrow specimens. Hum Pathol. 1988;94:54-58.
40. Goasguen JE, Kitchingman GR, Mirro J, et al. Lineage heterogeneity in acute leukemia. In: Knowles DM, ed. Neoplastic Hematopathology. Baltimore, MD: Williams & Wilkins; 1992:1351-1365.
41. Bakhshi A, Minowada J, Arnold A, et al. Lymphoid blast crises of chronic myelogenous leukemia represent stages in the development of B-cell precursors. N Engl J Med. 1983; 309:826-831.
42. Ekblom M, Borgstrom G, von Willebrand E, et al. Erythroid blast crisis in chronic myelogenous leukemia. Blood. 1983;62:591-596.
43. Bain B, Catovsky D, O'Brien M, et al. Megakaryoblastic transformation of chronic granulocytic leukemia: an electron microscopy and cytochemical study. J Clin Pathol. 1977;30:235-242.
44. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63:125-130.
45. Greaves MF. Analysis of the clinical and biological significance of lymphoid phenotypes in acute leukemia. Cancer Res. 1981;41:4752-4766.
46. Greaves MF. Differentiation-linked leukemogenesis in lymphocytes. Science. 1986;234:697-704.
47. Reinherz EL, Kung PC, Goldstein G, et al. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natt Acad Sci U S A. 1980;77:1588-1592.
48. MacKenzie MR, Lewis JP. Cytogenetic evidence that the malignant event in multiple myeloma occurs in a precursor lymphocyte. Cancer Genet Cytogenet. 1985;17:13-20.
49. Ocqueteau M, Orfao A, Garcia-Sanz R, et al. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol. 1996;95:489-493.